Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. Cobimetinib is a MEK inhibitor...
12 KB (890 words) - 22:25, 27 August 2024
dramatic efficacy in ECD patients harboring the BRAF V600E mutation. Cobimetinib, an oral inhibitor of MEK1 and MEK2, was approved in November 2022. Other...
22 KB (2,228 words) - 19:53, 23 August 2024
cycle of cobimetinib and vemurafenib, participants received atezolizumab 840 mg intravenous infusion every 2 weeks in combination with cobimetinib 60 mg...
43 KB (4,183 words) - 04:17, 1 October 2024
unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. Cobimetinib or XL518, approved by US FDA in Nov 2015 for use in combination with...
6 KB (719 words) - 23:12, 12 May 2024
2007, the company partnered its MEK inhibitor program with Genentech; cobimetinib (at that time XL-518) was part of this collaboration. Exelixis had filed...
12 KB (1,034 words) - 18:16, 11 July 2024
Cellcept (mycophenolate mofetil), for transplant rejection. Cotellic (cobimetinib), for melanoma. Cymevene (ganciclovir), for cytomegalovirus infection...
57 KB (5,195 words) - 10:21, 4 November 2024
Alectinib L01ED04 Brigatinib L01ED05 Lorlatinib L01EE01 Trametinib L01EE02 Cobimetinib L01EE03 Binimetinib L01EE04 Selumetinib L01EF01 Palbociclib L01EF02 Ribociclib...
12 KB (877 words) - 15:36, 25 January 2024
pulmonary fibrosis (IPF). Developed by Intermune, Inc. 2015: Cotellic (cobimetinib): For use in combination with ZELBORAF (vemurafenib), to treat metastatic...
32 KB (2,865 words) - 04:21, 4 October 2024
encorafenib, dabrafenib, and vemurafenib. Some MEK inhibitors include cobimetinib, CI-1040, PD0325901, binimetinib (MEK162), selumetinib, and trametinib...
24 KB (3,068 words) - 07:21, 7 June 2024
approved by the FDA. Another similar combination is vemurafenib and cobimetinib. Immunotherapy is also starting to play an important role in anaplastic...
20 KB (2,157 words) - 02:36, 2 September 2024
cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors. World Health Organization...
2 KB (87 words) - 04:20, 3 April 2023
antineoplastic agents against various types of cancer. MEK inhibitor cobimetinib has been investigated in pre-clinical lung cancer models in combination...
46 KB (5,492 words) - 05:56, 16 October 2024
planned including a trial of vemurafenib co-administered with GDC-0973 (cobimetinib), a MEK-inhibitor. After good results in 2014, the combination was submitted...
21 KB (1,815 words) - 16:50, 24 November 2024
Lestaurtinib Momelotinib Pacritinib Ruxolitinib MAP2K (MEK) Binimetinib Cobimetinib Selumetinib Trametinib EML4-ALK Crizotinib Entrectinib Lorlatinib Bruton's...
12 KB (821 words) - 02:57, 12 October 2024
a BRAF inhibitor can be restarted plus MEK inhibitors trametinib or cobimetinib. Interferon-alpha is an immune system hormone that is very helpful to...
53 KB (6,579 words) - 04:57, 12 November 2024
inhibitors: brigatinib+binimetinib, ceritinib+trametinib, and alectinib+cobimetinib. Results for the last two are expected around 2020-2021. The EGFR and...
17 KB (1,951 words) - 10:39, 25 January 2024
gov Clinical trial number NCT05034627 for "Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer"...
21 KB (2,547 words) - 03:32, 25 November 2024
leukemia Cetuximab EGFR Imclone / BMS Monoclonal antibody 2006 Mar (SCCHN) Cobimetinib MEK Exelixis / Genentech-Roche Small molecule 2015 Nov (Advanced melanoma...
23 KB (750 words) - 23:26, 13 August 2024
Lestaurtinib Momelotinib Pacritinib Ruxolitinib MAP2K (MEK) Binimetinib Cobimetinib Selumetinib Trametinib EML4-ALK Crizotinib Entrectinib Lorlatinib Bruton's...
12 KB (758 words) - 23:46, 14 March 2024